Open Beta
MetriLume

US marketsFLGT

SEC-sourced researchBeta

FLGT

Fulgent Genetics, Inc.

Company comparison ↗

Data passport

CIK
0001674930
Exchange
Nasdaq
Business activity
— · SIC 8071
Financial inputs
6/6
Filing date
Sep 3, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 289,213,000.0000 USD; December 2024: 283,470,000.0000 USD; December 2025: 322,671,000.0000 USD322.7M USD0 USD0December 2023December 2024December 2025
FLGT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023289,213,000.0000Feb 27, 2026
December 2024283,470,000.0000Feb 27, 2026
December 2025322,671,000.0000Feb 27, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025322,671,000.0000-60,513,000.0000-101,638,000.00001,213,525,000.0000106,810,000.0000Feb 27, 2026
December 2024283,470,000.0000-42,708,000.000021,060,000.00001,219,964,000.000090,805,000.0000Feb 27, 2026
December 2023289,213,000.0000-167,825,000.000027,003,000.0000——Feb 27, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$322.67MDecember 2025Feb 27, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$283.47MDecember 2024Feb 27, 202610-K
Net incomeNetIncomeLoss-$60.51MDecember 2025Feb 27, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$101.64MDecember 2025Feb 27, 202610-K
Total assetsAssets$1.21BDecember 2025Feb 27, 202610-K
Total liabilitiesLiabilities$106.81MDecember 2025Feb 27, 202610-K

New filings

Explore methodology ↗